Laia Garrigós

Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial

José Manuel Pérez-García, Marta Vaz Batista, Patricia Cortez et al. · Neuro-Oncology · 2022 · 248 citations · Full text

Medicine, Oncology, Pharmacology +17

Effect of a diet and physical activity intervention on body weight and nutritional patterns in overweight and obese breast cancer survivors

Noémie Travier, Ana Fonseca‐Nunes, Casimiro Javierre et al. · Medical Oncology · 2013 · 64 citations

Agriculture, Nutrition, Nutritional Sciences +17

Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer

Sònia Servitja, Xavier Nogués, Daniel Prieto‐Alhambra et al. · The Breast · 2011 · 47 citations

Medicine, Oncology, Pharmacology +16

Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study

Daniel Prieto‐Alhambra, Sònia Servitja, M K Javaid et al. · Breast Cancer Research and Treatment · 2012 · 39 citations

Medicine, Endocrinology, Nutritional Sciences +16

The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis

Marta Vaz Batista, José Manuel Pérez-García, Laia Garrigós et al. · Med · 2024 · 39 citations

Medicine, Oncology, Pharmacotherapy +16